334
Registered trials
149
Recruiting
154
Completed trials
149
Sponsors
26
Countries
Phase III:
138
Phase II/III:
19
Phase II:
127
Phase I/II:
26
Phase III/IV:
2
Phase IV:
8
Phase I:
1
Phase I (Other):
3
Phase I (FiH):
10
Oversight events:
11 serious breaches
71 temporary halts
7 urgent safety measures
5 unexpected events
9 corrective measures
across 37 trials
View oversight register →
Indications tested
Non-small cell lung cancer
49
Non-small cell lung cancer metastatic
19
Non-small cell lung cancer stage IV
12
Triple negative breast cancer
11
Small cell lung cancer extensive stage
10
Non-small cell lung cancer stage III
9
Non-small cell lung cancer stage IIIB
9
Fallopian tube cancer
8
Ovarian cancer
7
Breast cancer
5
Non-small cell lung cancer recurrent
5
Non-small cell lung cancer stage IIIA
5
Sponsors using this IMP
Merck Sharp & Dohme LLC
34
AstraZeneca AB
28
Bristol-Myers Squibb Services Unlimited Company
13
AbbVie Deutschland GmbH & Co. KG
8
F. Hoffmann-La Roche AG
7
Gilead Sciences Inc.
7
Intergroupe Francophone De Cancerologie Thoracique
7
Daiichi Sankyo Inc.
6
Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting
6
Janssen - Cilag International
6
Regeneron Pharmaceuticals Inc.
6
Genmab A/S
5
All trials
334 total-
HARMONi-3 Not authorised
-
SIOP PNET 5 medulloblastoma Pending
Showing 1–24 of 334 trials